Harmony Biosciences saw an improvement in its IBD SmartSelect Composite Rating Tuesday, from 91 to 97.
Discover The 3 Keys To Successful Stock Investing
The revised score means the stock currently tops 97% of all other stocks in terms of key performance metrics and technical strength. The best stocks tend to have a 95 or better grade as they begin to launch a significant move so be sure to keep that in mind when looking for the best stocks to buy and watch.
Harmony Biosciences broke out earlier, but has fallen back below the prior 35.40 entry from a consolidation. In the scenario where a stock breaks out then falls 7% or more below the entry price, it's considered a failed breakout. If that happens, it's best to wait for a new base to take shape.
The stock earns a 97 EPS Rating, which means its recent quarterly and annual earnings growth tops 97% of all stocks.
Its Accumulation/Distribution Rating of B shows moderate buying by institutional investors over the last 13 weeks.
The company posted a 17% EPS gain for Q1. Top line growth fell to 19%, down from 20% in the prior quarter.
Harmony Biosciences holds the No. 5 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
